Helsinn is co-anchoring the second 3B Future Health Fund, which will target oncology and rare disease therapeutics startups as it seeks a $118m close.
Pharmaceutical firm Helsinn has co-anchored the second iteration of Luxembourg-registered medical investment vehicle 3B Future Health Fund, which has a €100m ($118m) target for its close.
The vehicle is co-anchored with the Braglia family, with additional commitments by undisclosed private and institutional investors.
Lemanik Asset Management has been appointed as a fund manager for 3B Future Health Fund II, which will invest in early-stage companies located in Europe and the US that are developing treatments for cancers and rare diseases.
…
